Signaling Mechanisms of Bortezomib in TRAF3-deficient Mouse B Lymphoma and Human Multiple Myeloma Cells

Leukemia Research - United Kingdom
doi 10.1016/j.leukres.2015.12.005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Intracellular Glutathione Determines Bortezomib Cytotoxicity in Multiple Myeloma Cells

Blood Cancer Journal
OncologyHematology
2016English

Curcumin in Combination With Bortezomib Synergistically Induced Apoptosis in Human Multiple Myeloma U266 Cells

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2008English

The SRC Family Kinase LYN Redirects B Cell Receptor Signaling in Human SLP65-deficient B Cell Lymphoma Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2006English

Hedgehog and Retinoid Signaling Alters Multiple Myeloma Microenvironment and Generates Bortezomib Resistance

Journal of Clinical Investigation
Medicine
2016English

Sensitizing Human Multiple Myeloma Cells to the Proteasome Inhibitor Bortezomib by Novel Curcumin Analogs

International Journal of Molecular Medicine
MedicineGenetics
2011English

MicroRNA-324-5p Regulates Stemness, Pathogenesis and Sensitivity to Bortezomib in Multiple Myeloma Cells by Targeting Hedgehog Signaling

International Journal of Cancer
Cancer ResearchOncology
2017English

Establishment of a Bortezomib-Resistant Chinese Human Multiple Myeloma Cell Line: MMLAL

Cancer Cell International
Cancer ResearchOncologyGenetics
2013English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Efficacy of Subcutaneous Bortezomib in the Management of Patients With Multiple Myeloma or Relapsed Mantle Cell Lymphoma

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy